Safety and Efficacy of YB-1113 in Treatment of POI
A Phase 1 Study of the Safety and Efficacy of YB-1113 in Treatment of Premature Ovarian Insufficiency (POI) Via Intravenous Infusion
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jennifer Wang
- Phone Number: 949-333-3636
- Email: jenniferw@brightcellinc.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Female, 18 to <40 years old, who are seeking fertility or preservation of fertility
- Oligo/Amenorrhea for at least 4 months
- At least two menopausal FSH levels (≥ 25 IU/L) with 4 to 6 weeks interval.
- AMH levels ≤ 1.0 ng/mL (measured on day 2-5 of the menstrual period).
- Subjects who are generally healthy by laboratory tests (normal complete blood count (CBC), comprehensive metabolic panel (CMP), and urinalysis) at screening
- For subjects who had contraception before, the duration of amenorrhea should be more than 3 months after discontinuation of the oral contraception pill (OCP) or more than 6 months after discontinuation of Depo Provera (or similar) therapies
Key Exclusion Criteria:
- 1. Primary amenorrhea or FSH ≥ 40 IU/L
- Presence of contraindications to pregnancy
- POI due to cytotoxic chemotherapy or radiation therapy
- Subjects with FMR1 premutation (fragile X syndrome), a BMP15 mutation or family history of POI
- Subjects under hormonal treatments including hormone replacement therapy (HRT) for osteoporosis, cardiovascular disease, or recalcitrant vasomotor symptomatology.
- Washout period less than 3 months for HRT.
- Subjects with a history of breast cancer or other estrogen responsive cancer.
- Subjects with existing malignant neoplasm, under active management for malignant neoplasm or under active surveillance for malignant neoplasm.
- Subjects with history of thromboembolic events such as pulmonary embolism, stroke, or ischemic heart disease
- Subjects with uncontrolled hypertension, kidney disease, liver disease, or polycystic ovary syndrome (PCOS)
- Subjects with endocrinopathies including Cushing's disease, thyroid disease, congenital adrenal hyperplasia and hyperprolactinemia.
- Subjects under active management for autoimmune disease.
- Subjects with intra-uterine devices (IUDs).
- Subjects who are pregnant, breastfeeding, or whose urinary pregnancy test is positive before participation in the study.
- Subjects who are allergic to low-molecular-weight heparin sodium or human albumin.
- Subjects with polyglandular autoimmune disease or other conditions require chronic administration of steroids higher than 30 mg/day of hydrocortisone or its equivalent
- Subjects with hereditary or acquirement coagulopathies, including but not limited to hemophilia, Von Willebrand disease, liver disease, Vitamin K deficiency, and platelet disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Low-dose
Low-dose YB-1113
|
Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
|
|
Experimental: High-dose
High-dose YB-1113
|
Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of treatment-emergent adverse events (AE)
Time Frame: 52 weeks
|
Reported treatment-related AE and serious adverse events (SAE)
|
52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood anti-Müllerian hormone (AMH) level
Time Frame: 2, 6, 12, 24, and 52 weeks
|
Changes of AMH level from baseline
|
2, 6, 12, 24, and 52 weeks
|
|
Follicle-stimulating hormone (FSH) and estradiol (E2) levels
Time Frame: 2, 6, 12, 24, and 52 weeks
|
Changes of FSH and E2 from baseline
|
2, 6, 12, 24, and 52 weeks
|
|
Antral follicle counts (AFC)
Time Frame: 2, 6, 12, 24, and 52 weeks
|
Changes of AFC numbers from baseline
|
2, 6, 12, 24, and 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- YB1113-POI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.